E 2027

Drug Profile

E 2027

Alternative Names: E2027

Latest Information Update: 16 Mar 2017

Price : $50

At a glance

  • Originator Eisai Inc
  • Class
  • Mechanism of Action Phosphodiesterase 9A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 01 Jan 2017 Eisai completes a phase I drug-drug interaction trial in Healthy volunteers in USA (NCT02947711)
  • 01 Oct 2016 Eisai initiates a phase I drug-drug interaction trial in Healthy volunteers in USA (PO, Capsule) (NCT02947711)
  • 01 Aug 2016 Eisai initiates a phase I trial in Healthy volunteers in USA (PO) (NCT02873156)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top